An observational study in Nevi, Dysplastic, sponsored by Orlucent, Inc. Enrolling by invitation at 1 site in United States. Per ClinicalTrials.gov, last updated 2024-02-07.
Sponsored by Orlucent, Inc · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Dysplastic Nevus Syndrome with a site in United States — 5 open to participants now, 6 under way, 1 of them phase 3. Dysplastic Nevus Syndrome · United States.
Among the 17 studies in Dysplastic Nevus Syndrome with a site in United States, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2023, is one of 11 observational ones, and was the 15th registered.
24 studies on the registry are indexed under Dysplastic Nevus Syndrome; 7 are open to participants now.
Browse Dysplastic Nevus Syndrome studies →5 of the 17 studies in Dysplastic Nevus Syndrome with a site in United States are open now. Recruiting first, the newest first:
ECOG-ACRIN Cancer Research Group · Sites in United States
Ages 18+
John Kirkwood · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 4 wk–99 yrs · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Dysplastic Nevus Syndrome studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 1
First in 1999; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 500 is above the median of 283 across 16 observational studies indexed under Dysplastic Nevus Syndrome.
Median enrollment 78 across the 6 interventional studies, 265 across the 11 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 17 have an industry lead sponsor. The 10 most frequent:
Orlucent, Inc is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Orlucent, Inc has 3 studies filed under Dysplastic Nevus Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Dysplastic Nevus Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692596H. Lee Moffitt Cancer Center and Research InstituteThe Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Dysplastic Nevus Syndrome with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a post study histology analysis from previously obtained pathology slides.
This is a post study histology analysis. Pathologists will use digital histology slide scans of suspicious nevus/nevi obtained from previously conducted studies to provide histopathology gradations of histological features as outlined in the Orlucent histology atlas (LBL0713 Histopathology Atlas for Grading of Dysplastic Nevi and DEF0713-1 Histopathology Definitions for LBL0713).
Previous consented subject\'s scans from the Orlucent OMS002, SFI001 or SFI003 Studies and
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Study Success
This is a data collection study. Study success is considered when the interpathology agreement is improved when compared to the agreement identified in Elmore et al. \[5\]. \[(classes/agreement): class I (eg, nevus or mild atypia) / 92% (95% confidence interval 90% to 94); class II (eg, moderate atypia) / 25% (22% to 28%); III (eg, severe atypia or melanoma in situ) / 40% (37% to 44%); IV (eg, pathologic stage T1a (pT1a) early invasive melanoma) / 43% (39% to 46%); and V (eg, ≥pT1b invasive melanoma) / 72% (69% to 75%).\]
Time frame: 8 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Jun 2024, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Orlucent, Inc